Alcohol Pharmacotherapy for HIV+ Prisoners
Diseases and Conditions Researched
AIDS; Alcohol Dependence; Hazardous Drinking; Human Immunodeficiency Virus; Problem Drinking
What is the purpose of this trial?
This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.
Click here for detailed participation information for this trial.
|Sponsors:||National Institute on Alcohol Abuse and Alcoholism (NIAAA); Yale University|
|Dates:||February 19, 2010|
|Last Updated:||July 8, 2014|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.